Drugs / NSA-789
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00892021 | May → Oct 2009 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT00781794 | Jan → Aug 2009 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT00795730 | Jan → May 2009 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00633048 | Mar → May 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00619736 | Mar → Sep 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NSA-789 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00781794 ↗ |
| Route | Oral | “Administered Orally” NCT00619736 ↗ |